

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)							ATTY. DOCKET NO. PC23170A		SERIAL NO. 10/596,504			
APPLICANT Hua Zhu Ke												
FILING DATE							GROUP					
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	REMARKS IF APPROPRIATE
US	2	8	3	4	7	1	2	5-13-58	Bell, et al			
US	3	8	2	2	2	8	7	7-2-74	Bolger, et al	260	3285	
US	3	9	1	6	8	9	9	11-4-75	Thieuwes, et al	128	260	
US	3	9	7	7	4	0	4	8-31-78	Thieuwes	128	260	
US	4	4	1	8	0	6	8	11-29-83	Jones, et al	424	267	
US	4	8	2	3	6	6	0	11-16-86	Richardson	514	514	
US	4	6	9	8	9	4	9	9-29-87	Tohvela, et al	514	548	
US	4	7	9	2	4	4	8	12-20-88	Renede	424	438	
US	4	8	3	9	1	5	5	6-13-89	McCasque	424	1,1	
US	4	9	9	8	2	2	5	2-26-91	Tohvela, et al	514	428	
US	5	0	4	7	4	9	1	9-10-91	Schickaneder, et al	514	548	
US	5	3	9	3	7	6	3	2-28-95	Black, et al	514	333	
US	5	4	5	5	0	4	6	10-3-95	Bachwal, et al	424	457	
US	5	4	5	7	1	1	7	10-10-95	Black, et al	514	337	
US	5	4	6	4	8	4	5	11-7-95	Black, et al	514	328	
US	5	4	7	8	8	4	7	12-26-95	Desper	514	333	
US	5	4	8	4	7	9	5	1-16-96	Bryant, et al	514	319	
US	5	5	1	2	2	9	7	4-30-96	Bachwal	424	451	
US	5	5	5	2	4	1	2	9-3-96	Cameron, et al	514	317	
US	5	6	1	2	0	5	9	3-18-97	Cardinal, et al	424	495	
US	5	6	4	1	7	9	0	6-24-97	Desper	514	333	
US	5	6	9	8	2	2	0	12-16-97	Cardinal, et al	424	451	
US	5	7	8	0	4	9	7	7-14-98	Miller, et al	514	414	
US	5	8	2	7	5	3	8	10-27-98	Cussler, et al	424	473	
US	5	8	8	0	1	3	7	9-9-99	Miller, et al	514	323	
US	5	9	8	5	9	1	0	11-16-99	Miller, et al	514	415	
US	5	9	9	8	4	0	2	12-7-99	Miller, et al	514	212	

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>							ATTY. DOCKET NO. PC23170A			SERIAL NO. 10/596,504				
							APPLICANT Hua Zhu Ke							
							FILING DATE			GROUP				
US	6	2	0	4	2	8	6	3-20-01	Cameron, et al	514	428			
US	6	5	5	2	0	6	7	4-22-03	Cameron, et al	514	424			
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
	EP	0	3	7	8	4	0					4	1-10-90	European
	EP	0	6	0	5	1	9	3	12-22-93	European	A61K	31/40		
	EP	0	8	0	2	1	8	3	4-15-97	European	C07D	209/10		
	WO	9	5	1	0	5	1	3	4-20-95	International	C07D	333/56		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
	US Patent Application Publication No. US 2002/00004495, Pub. Date: 1-10-02, Herede, et al; US. Class 514/81													
	US Patent Application Publication No. US 2002/0065308, Pub. Date: 6-30-02, Cameron, et al; US. Class 514/381													
	US Patent Application Publication No. US 2003/0149086, Pub. Date: 8-17-03, Cameron, et al; US. Class 514/385													
	Arrenbrech, et al., <i>Osteoporosis International</i> , "Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal woman", Vol. 13, No. 2, pp. 176-183 (2002)													
	Black, et al., <i>Journal of Clinical Investigation</i> .. "Raloxifene (LY138481 HCl) Prevents Bone Loss and Reduces Serum Cholesterol Without Causing Uterine Hypertrophy in Ovariectomized Rats", Vol. 93, pp. 63-69, (1994)													
	Capony et al., <i>Molecular Cell Endocrinology</i> , "In Vivo effect of anti-estrogens on the localization and replenishment of estrogen receptor", Vol. 3, pp. 233, (1975)													
	Clark, et al., <i>Steroids</i> , "Estrogen receptor anti-estrogen complex: Atypical binding by uterine nuclei and effects on uterine growth", Vol. 22 (5), pp. 707-718 (1973)													
	Delimes, et al., <i>New England Journal of Medicine</i> , "Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentration, and Uterine Endometrium in Postmenopausal Women", Vol. 337, pp.1641-1647, (1997)													
	Geuthner, et al., <i>Journal of Medicinal Chemistry</i> , "(S)-(+)-4-[7-(2,2-Dimethyl-1-oxopro- pyoxy-4-methyl-2-[4-(2-(1-piperidinyl)- ethoxyphenyl]-2H-1-benzopyran-3-yl] phenyl 2,2-Dimethylpropanate (EM-800): A Highly Potent, Specific, and Orally Active Nonsteroidal Antiestrogen", Vol. 40, pp. 2117-2122 (1997)													
	Hansson et al., <i>Journal of Pharm. Sci.</i> , "Perforated Coated Tablets for Controlled Release of Drugs at a Constant Rate", Vol. 77, pp. 322-324, (1988)													
	Osteoporosis Conference Script No. 1812-13, Apr. 16-20, pp. 29-31, (1993)													
	Shen et al., <i>Journal of Clinical Investigation</i> , "Effects of Reciprocal Treatment with Estrogen and Estrone plus Parathyroid Hormone on Bone Structure and Strength in Ovariectomized Rats", Vol. 96, pp. 2331-2338, (1995)													
	Siris, et al., <i>JAMA</i> 2001, "Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women", Vol. 286(22), pp. 2815-2822 (2001)													
	Tang et al., <i>Journal of Bone Mineral Research</i> , "Restoring and Maintaining Bone in Osteogenic Female Rat Skeleton: I. Changes in Bone Mass and Structure", Vol. 7 (9), pp. 1093-1104, (1992)													
	Wilson et al., <i>Journal of Medicinal Chemistry</i> , "3-[4-(1,2-Diphenylbut-1-enyl) phenyl] acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats", Vol. 37, pp.1550-1552, (1994)													
	World Health Organization, "Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis, Report of a World Health Organization Study Group. World Health Organization Technical Series 843", (1994)													

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. PC23170A	SERIAL NO. 10/596,504
		APPLICANT Hua Zhu Ke	
		FILING DATE	GROUP
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
EXAMINER		DATE CONSIDERED	
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			

Conforms with FORM PTO/FB-A820

INFORMATION DISCLOSURE